M
Mind Medicine (MindMed) Inc. (MNMD)
NMS – Real Time Price. Currency in USD
15.02
+0.15 (1.01%)
At close: Jan 14, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
15.02
+0.15 (1.01%)
At close: Jan 14, 2026, 4:00 PM EDT
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
| Name | Position |
|---|---|
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer |
| Dr. Gregg Pratt Ph.D. | Chief Regulatory & Quality Assurance Officer |
| Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor |
| Mr. Leonard Latchman | Co-Founder |
| Mr. Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Peter Mack | Senior Vice President of Pharmaceutical Development & Operations |
There is no data to display
| Mr. Robert Barrow | CEO & Director |
| Ms. Beth Calitri | Vice President of Corporate Communications |
| Ms. Brandi L. Roberts CPA, M.B.A. | Chief Financial Officer |
| Ms. Stephanie Fagan | Chief Corporate Affairs Officer |